Credit Suisse has maintained 'Underperform' view on the stock with a target price at Rs 800 per share.

The drug maker had reported Rs 456.87 crore profit in the year-ago quarter.

Trend Intensity (TI) indicator is up at 21, suggesting prices are trending upwards. MACD is also positive and above its signal line.